Pioglitazone, but not metformin, reduces liver fat in Type-2 diabetes mellitus independent of weight changes

Journal of Diabetes and its Complications

Volumn 24, Issue 5, 2010, Pages 289-296

  Gupta, Alok K ^a   Bray, George A ^a   Greenway, Frank L ^a   Martin, Corby K ^a   Johnson, William D ^a   Smith, Steven R ^a  

^a PENNINGTON BIOMEDICAL RESEARCH CENTER   (United States)

Author keywords

Adiponectin; ALT; Cardiovascular disease; Diabetes; hs CRP; Metformin; NAFLD; NASH; Obesity, Adipose tissue

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ADIPONECTIN; C REACTIVE PROTEIN; FAT; INSULIN; METFORMIN; PIOGLITAZONE; SULFONYLUREA;

ADULT; AGED; ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; FEMALE; HUMAN; LIPID STORAGE; LIVER; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; WEIGHT CHANGE; WEIGHT REDUCTION;

ADIPONECTIN; ADULT; AGED; BODY WEIGHT; C-REACTIVE PROTEIN; DIABETES MELLITUS, TYPE 2; DIET, REDUCING; FATTY LIVER; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; LIVER; MALE; METFORMIN; MIDDLE AGED; THIAZOLIDINEDIONES;

EID: 77956230965     PISSN: 10568727     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jdiacomp.2009.05.004     Document Type: Article

References (41)

1. Angelico F., Burattin M., Alessandri C., Del Ben M., and Lirussi F. Drugs improving insulin resistance for non-alcoholic fatty liver disease and/or non-alcoholic steatohepatitis Cochrane Database of Systematic Reviews (Online) 1 2007, January CD005166
2. Assy N., Hussein O., and Abassi Z. Weight loss induced by orlistat reverses fatty infiltration and improves hepatic fibrosis in obese patients with non-alcoholic steatohepatitis Gut 56 3 2007, March 443 444
3. Belfort R., Harrison S.A., Brown K., and Darland C. A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis New England Journal of Medicine 355 22 2006 2297 2307
4. Berg A.H., and Scherer P.E. Adipose tissue, inflammation, and cardiovascular disease Circulation Research 96 9 2005 939 949
5. Björnsson E. The clinical aspects of non-alcoholic fatty liver disease Minerva Gastroenterologica e Dietologica 54 1 2008 7 18 (Review)
6. Boppidi H., and Daram S.R. Nonalcoholic fatty liver disease: Hepatic manifestation of obesity and the metabolic syndrome Postgraduate Medicine 120 2 2008 E01 E07
7. Brock R.W., and Dorman R.B. Obesity, insulin resistance and hepatic perfusion Microcirculation 14 4-5 2007 339 347
8. Chalasani N.P., Sanyal A.J. The NASH CRN Research Group. Pioglitazone versus vitamin E versus placebo for the treatment of non-diabetic patients with non-alcoholic steatohepatitis: PIVENS trial design Contemporary Clinical Trials 30 1 2008, September 88 96
9. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation and treatment of high blood cholesterol in adults (Adult Treatment Panel III) JAMA 285 2001 2486 2497
10. Farrell G.C., and Larter C.Z. Nonalcoholic fatty liver disease: From steatosis to cirrhosis Hepatology 43 2 Suppl. 1 2006 S99 S112 (Review)
11. Fonseca V. Effect of thiazolidinediones on body weight in patients with diabetes mellitus American Journal of Medicine 115 Suppl. 8A 2003 42S 48S (Review)
12. Ford E.S. The metabolic syndrome and mortality from cardiovascular disease and all-causes: Findings from the National Health and Nutrition Examination Survey II Mortality Study Atherosclerosis 173 2 2004 309 314
13. Giannini S., Serio M., and Galli A. Pleiotropic effects of thiazolidinediones: Taking a look beyond antidiabetic activity Journal of Endocrinological Investigation 27 10 2004 982 991
14. Goodpaster B.H., Thaete F.L., and Kelley D.E. Thigh adipose tissue distribution is associated with insulin resistance in obesity and in Type 2 diabetes mellitus American Journal of Clinical Nutrition 71 4 2000 885 892
15. Granberry M.C., and Fonseca V.A. Cardiovascular risk factors associated with insulin resistance: Effects of oral antidiabetic agents American Journal of Cardiovascular Drugs 5 3 2005 201 209
16. Gupta A.K., Smith S.R., Greenway F.L., and Bray G.A. Pioglitazone treatment in Type 2 diabetes mellitus when combined with portion control diet modifies the metabolic syndrome Diabetes, Obesity & Metabolism 11 4 2009 330 337
17. Hamaguchi M., Kojima T., Takeda N., and Nagata C. Nonalcoholic fatty liver disease is a novel predictor of cardiovascular disease World Journal of Gastroenterology 13 10 2007 1579 1584
18. Hamaguchi M., Kojima T., Takeda N., and Nakagawa T. The metabolic syndrome as a predictor of nonalcoholic fatty liver disease Annals of Internal Medicine 143 10 2005 722 728
19. Khashab, M., Chalasani, N. (2007). Use of insulin sensitizers in NASH. Endocrinology and Metabolism Clinics of North America, 36(4), 1067-87; xi. (Review).
20. Kostadinova R., Wahli W., and Michalik L. PPAR's in diseases: Control mechanisms of inflammation Current Medical Chemistry 12 25 2005 2995 3009
21. Kowalska I., Straczkowski M., Nikolajuk A., and Adamska A. Insulin resistance, serum adiponectin, and proinflammatory markers in young subjects with the metabolic syndrome Metabolism 57 11 2008 1539 1544
22. Kunde S.S., Lazenby A.J., Clements R.H., and Abrams G.A. Spectrum of NAFLD and diagnostic implications of the proposed new normal range for serum ALT in obese women Hepatology 42 3 2005 650 656
23. Lin P.H., Proschan M.A., Bray G.A., Fernandez C.P., Hoben K., Most-Windhauser M., Karanja N., Obarzanek E. DASH Collaborative Research Group Estimation of energy requirements in a controlled feeding trial American Journal of Clinical Nutrition 2003 639 645
24. Madsen E.L., Rissanen A., Bruun J.M., and Skogstrand K. Weight loss larger than 10% is needed for general improvement of levels of circulating adiponectin and markers of inflammation in obese subjects: A 3-year weight loss study European Journal of Endocrinology 158 2 2008 179 187
25. Marchesini G., Brizi M., Bianchi G., and Tomassetti S. Nonalcoholic fatty liver disease: A feature of the metabolic syndrome Diabetes 50 8 2001 1844 1850
26. Montani J.P., Carroll J.F., Dwyer T.M., Antic V., Yang Z., and Dulloo A.G. Ectopic fat storage in heart, blood vessels and kidneys in the pathogenesis of cardiovascular diseases International Journal of Obesity and Related Metabolic Disorders 28 Suppl. 4 2004 S58 S65
27. Musunuru K., Kral B.G., Blumenthal R.S., Fuster V., and Mora S. The use of high-sensitivity assays for C-reactive protein in clinical practice Nature Clinical Practice Cardiovascular Medicine 5 10 2008 621 635 (Electronic publication 2008 Aug 19)
28. Nedvídková J., Smitka K., Kopský V., and Hainer V. Adiponectin, an adipocyte-derived protein Physiological Research 54 2 2005 133 140 (Review)
29. Panagiotakos D.B., Pitsavos C., Skoumas Y., Lentzas Y., and Stefanadis C. Five-year incidence of Type 2 diabetes mellitus among cardiovascular disease-free Greek adults: Findings from the ATTICA study Vascular Health and Risk Management 4 3 2008 691 698
30. Prati D., Taioli E., and Zanella A. Updated definitions of healthy ranges for serum alanine aminotransferase levels Annals of Internal Medicine 137 1 2002 1 10
31. Promrat K., Lutchman G., Uwaifo G.I., and Freedman R.J. A pilot study of pioglitazone treatment for nonalcoholic steatohepatitis Hepatology 39 1 2004 188 196
32. Qureshi K., and Abrams G.A. Metabolic liver disease of obesity and role of adipose tissue in the pathogenesis of nonalcoholic fatty liver disease World Journal of Gastroenterology 13 26 2007 3540 3553 (Review)
33. Ridker P.M., and Morrow D.A. C-reactive protein, inflammation, and coronary risk Cardiology Clinics 21 3 2003 315 325 (Review)
34. Ruhl, C.E., Everhart, J.E., (2004) Epidemiology of nonalcoholic fatty liver. Clinics in Liver Disease, 8(3), 501-19, vii. (Review).
35. Smith S.R., De Jonge L., Volaufova J., Li Y., Xie H., and Bray G.A. Effect of pioglitazone on body composition and energy expenditure: A randomized controlled trial Metabolism 54 2005 24 32
36. Sung K.C., Ryan M.C., and Wilson A.M. The severity of nonalcoholic fatty liver disease is associated with increased cardiovascular risk in a large cohort of non-obese Asian subjects Atherosclerosis 203 2 2008, July 581 586
37. Swarbrick M.M., and Havel P.J. Physiological, pharmacological, and nutritional regulation of circulating adiponectin concentrations in humans Metabolic Syndrome and Related Disorders 6 2 2008 87 102 (Review)
38. Targher G., Bertolini L., Padovani R., Rodella S., Tessari R., Zenari L., Day C., and Arcaro G. Prevalence of nonalcoholic fatty liver disease and its association with cardiovascular disease among type 2 diabetic patients Diabetes Care 30 5 2007 1212 1218
39. Waugh J., Keating G.M., Plosker G.L., Easthope S., and Robinson D.M. Pioglitazone: A review of its use in Type 2 diabetes mellitus Drugs 66 3 2006 340 341
40. Weiss R. Fat distribution and storage: How much, where, and how? European Journal of Endocrinology 157 Suppl. 1 2007 S39 S45 (Review)
41. Younossi Z.M., Gramlich T., Matteoni C.A., Boparai N., and McCullough A.J. Nonalcoholic fatty liver disease in patients with Type 2 diabetes Clinical Gastroenterology and Hepatology 2 3 2004 262 265